1. The Shulan (Hangzhou) Hospital, Affiliated to Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310022, China 2. Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, China 3. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China 4. Innovative Precision Medicine (IPM) Group, Hangzhou 311215, China
The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was identified in December 2019. The symptoms include fever, cough, dyspnea, early symptom of sputum, and acute respiratory distress syndrome (ARDS). Mesenchymal stem cell (MSC) therapy is the immediate treatment used for patients with severe cases of COVID-19. Herein, we describe two confirmed cases of COVID-19 in Wuhan to explore the role of MSC in the treatment of COVID-19. MSC transplantation increases the immune indicators (including CD4 and lymphocytes) and decreases the inflammation indicators (interleukin-6 and C-reactive protein). High-flow nasal cannula can be used as an initial support strategy for patients with ARDS. With MSC transplantation, the fraction of inspired O2 (FiO2) of the two patients gradually decreased while the oxygen saturation (SaO2) and partial pressure of oxygen (PO2) improved. Additionally, the patients’ chest computed tomography showed that bilateral lung exudate lesions were adsorbed after MSC infusion. Results indicated that MSC transplantation provides clinical data on the treatment of COVID-19 and may serve as an alternative method for treating COVID-19, particularly in patients with ARDS.
C Huang, Y Wang, X Li, L Ren, J Zhao, Y Hu, L Zhang, G Fan, J Xu, X Gu, Z Cheng, T Yu, J Xia, Y Wei, W Wu, X Xie, W Yin, H Li, M Liu, Y Xiao, H Gao, L Guo, J Xie, G Wang, R Jiang, Z Gao, Q Jin, J Wang, B Cao. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506 https://doi.org/10.1016/S0140-6736(20)30183-5
pmid: 31986264
2
Q Li, X Guan, P Wu, X Wang, L Zhou, Y Tong, R Ren, KSM Leung, EHY Lau, JY Wong, X Xing, N Xiang, Y Wu, C Li, Q Chen, D Li, T Liu, J Zhao, M Liu, W Tu, C Chen, L Jin, R Yang, Q Wang, S Zhou, R Wang, H Liu, Y Luo, Y Liu, G Shao, H Li, Z Tao, Y Yang, Z Deng, B Liu, Z Ma, Y Zhang, G Shi, TTY Lam, JT Wu, GF Gao, BJ Cowling, B Yang, GM Leung, Z Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199–1207 https://doi.org/10.1056/NEJMoa2001316
pmid: 31995857
3
XW Xu, XX Wu, XG Jiang, KJ Xu, LJ Ying, CL Ma, SB Li, HY Wang, S Zhang, HN Gao, JF Sheng, HL Cai, YQ Qiu, LJ Li. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606 https://doi.org/10.1136/bmj.m606
pmid: 32075786
4
ML Holshue, C DeBolt, S Lindquist, KH Lofy, J Wiesman, H Bruce, C Spitters, K Ericson, S Wilkerson, A Tural, G Diaz, A Cohn, L Fox, A Patel, SI Gerber, L Kim, S Tong, X Lu, S Lindstrom, MA Pallansch, WC Weldon, HM Biggs, TM Uyeki, SK; PillaiWashington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929–936 https://doi.org/10.1056/NEJMoa2001191
pmid: 32004427
5
S Xia, M Liu, C Wang, W Xu, Q Lan, S Feng, F Qi, L Bao, L Du, S Liu, C Qin, F Sun, Z Shi, Y Zhu, S Jiang, L Lu. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 2020; 30: 343–355 https://doi.org/10.1038/s41422-020-0305-x
pmid: 32231345
6
WJ Guan, ZY Ni, Y Hu, WH Liang, CQ Ou, JX He, L Liu, H Shan, CL Lei, DSC Hui, B Du, LJ Li, G Zeng, KY Yuen, RC Chen, CL Tang, T Wang, PY Chen, J Xiang, SY Li, JL Wang, ZJ Liang, YX Peng, L Wei, Y Liu, YH Hu, P Peng, JM Wang, JY Liu, Z Chen, G Li, ZJ Zheng, SQ Qiu, J Luo, CJ Ye, SY Zhu, NS; China Medical Treatment Expert Group for COVID-19 Zhong. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708–1720 https://doi.org/10.1056/NEJMoa2002032
pmid: 32109013
P Zhou, XL Yang, XG Wang, B Hu, L Zhang, W Zhang, HR Si, Y Zhu, B Li, CL Huang, HD Chen, J Chen, Y Luo, H Guo, RD Jiang, MQ Liu, Y Chen, XR Shen, X Wang, XS Zheng, K Zhao, QJ Chen, F Deng, LL Liu, B Yan, FX Zhan, YY Wang, GF Xiao, ZL Shi. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270–273 https://doi.org/10.1038/s41586-020-2012-7
pmid: 32015507
9
H Lu, CW Stratton, YW Tang. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol 2020; 92(4): 401–402 https://doi.org/10.1002/jmv.25678
pmid: 31950516
10
R Lu, X Zhao, J Li, P Niu, B Yang, H Wu, W Wang, H Song, B Huang, N Zhu, Y Bi, X Ma, F Zhan, L Wang, T Hu, H Zhou, Z Hu, W Zhou, L Zhao, J Chen, Y Meng, J Wang, Y Lin, J Yuan, Z Xie, J Ma, WJ Liu, D Wang, W Xu, EC Holmes, GF Gao, G Wu, W Chen, W Shi, W Tan. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395(10224): 565–574 https://doi.org/10.1016/S0140-6736(20)30251-8
pmid: 32007145
11
Q Zhang, Y Wang, C Qi, L Shen, J Li. Clinical trial analysis of 2019-nCoV therapy registered in China. J Med Virol 2020; 92(6): 540–545 https://doi.org/10.1002/jmv.25733
Z Xu, L Shi, Y Wang, J Zhang, L Huang, C Zhang, S Liu, P Zhao, H Liu, L Zhu, Y Tai, C Bai, T Gao, J Song, P Xia, J Dong, J Zhao, FS Wang. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420–422 https://doi.org/10.1016/S2213-2600(20)30076-X
pmid: 32085846
M Shi, Z Liu, Y Wang, R Xu, Y Sun, M Zhang, X Yu, H Wang, L Meng, H Su, L Jin, FS Wang. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Transl Med 2017; 6(12): 2053–2061 https://doi.org/10.1002/sctm.17-0134
pmid: 29178564
18
ARR Weiss, MH Dahlke. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol 2019; 10: 1191 https://doi.org/10.3389/fimmu.2019.01191
pmid: 31214172
19
RM Samsonraj, M Raghunath, V Nurcombe, JH Hui, AJ van Wijnen, SM Cool. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 2017; 6(12): 2173–2185 https://doi.org/10.1002/sctm.17-0129
pmid: 29076267
20
S Hashmi, M Ahmed, MH Murad, MR Litzow, RH Adams, LM Ball, VK Prasad, P Kebriaei, O Ringden. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol 2016; 3(1): e45–e52 https://doi.org/10.1016/S2352-3026(15)00224-0
pmid: 26765648
21
J Liang, H Zhang, W Kong, W Deng, D Wang, X Feng, C Zhao, B Hua, H Wang, L Sun. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther 2018; 9(1): 312 https://doi.org/10.1186/s13287-018-1053-4
pmid: 30428931
22
F Gao, SM Chiu, DA Motan, Z Zhang, L Chen, HL Ji, HF Tse, QL Fu, Q Lian. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 2016; 7(1): e2062 https://doi.org/10.1038/cddis.2015.327
pmid: 26794657
23
LL de Castro, M Lopes-Pacheco, DJ Weiss, FF Cruz, PRM Rocco. Current understanding of the immunosuppressive properties of mesenchymal stromal cells. J Mol Med (Berl) 2019; 97(5): 605–618 https://doi.org/10.1007/s00109-019-01776-y
pmid: 30903229
24
L Saldaña, F Bensiamar, G Vallés, FJ Mancebo, E García-Rey, N Vilaboa. Immunoregulatory potential of mesenchymal stem cells following activation by macrophage-derived soluble factors. Stem Cell Res Ther 2019; 10(1): 58 https://doi.org/10.1186/s13287-019-1156-6
pmid: 30760316
25
M Khoury, PRM Rocco, DG Phinney, M Krampera, I Martin, S Viswanathan, JA Nolta, K LeBlanc, J Galipeau, DJ Weiss. Cell-based therapies for COVID-19: proper clinical investigations are essential. Cytotherapy 2020; [Epub ahead of print] doi: 10.1016/j.jcyt.2020.04.089 https://doi.org/10.1016/j.jcyt.2020.04.089
26
JG Wilson, KD Liu, H Zhuo, L Caballero, M McMillan, X Fang, K Cosgrove, R Vojnik, CS Calfee, JW Lee, AJ Rogers, J Levitt, J Wiener-Kronish, EK Bajwa, A Leavitt, D McKenna, BT Thompson, MA Matthay. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015; 3(1): 24–32 https://doi.org/10.1016/S2213-2600(14)70291-7
pmid: 25529339
27
X Meng, TE Ichim, J Zhong, A Rogers, Z Yin, J Jackson, H Wang, W Ge, V Bogin, KW Chan, B Thébaud, NH Riordan. Endometrial regenerative cells: a novel stem cell population. J Transl Med 2007; 5(1): 57 https://doi.org/10.1186/1479-5876-5-57
pmid: 18005405
28
W Zuo, B Xie, C Li, Y Yan, Y Zhang, W Liu, J Huang, D Chen. The clinical applications of endometrial mesenchymal stem cells. Biopreserv Biobank 2018; 16(2): 158–164 https://doi.org/10.1089/bio.2017.0057
pmid: 29265881
29
L Chen, J Qu, C Xiang. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther 2019; 10(1): 1 https://doi.org/10.1186/s13287-018-1105-9
pmid: 30606242
30
Z Yan, F Guo, Q Yuan, Y Shao, Y Zhang, H Wang, S Hao, X Du. Endometrial mesenchymal stem cells isolated from menstrual blood repaired epirubicin-induced damage to human ovarian granulosa cells by inhibiting the expression of Gadd45b in cell cycle pathway. Stem Cell Res Ther 2019; 10(1): 4 https://doi.org/10.1186/s13287-018-1101-0
pmid: 30606243
31
L Chen, C Zhang, L Chen, X Wang, B Xiang, X Wu, Y Guo, X Mou, L Yuan, B Chen, J Wang, C Xiang. Human menstrual blood-derived stem cells ameliorate liver fibrosis in mice by targeting hepatic stellate cells via paracrine mediators. Stem Cells Transl Med 2017; 6(1): 272–284 https://doi.org/10.5966/sctm.2015-0265
pmid: 28170193
32
M Khanmohammadi, S Khanjani, H Edalatkhah, AH Zarnani, H Heidari-Vala, M Soleimani, K Alimoghaddam, S Kazemnejad. Modified protocol for improvement of differentiation potential of menstrual blood-derived stem cells into adipogenic lineage. Cell Prolif 2014; 47(6): 615–623 https://doi.org/10.1111/cpr.12133
pmid: 25252214
33
L Chen, J Qu, T Cheng, X Chen, C Xiang. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther 2019; 10(1): 406 https://doi.org/10.1186/s13287-019-1503-7
pmid: 31864423
34
J Chen, C Hu, L Chen, L Tang, Y Zhu, X Xu, L Chen, H Gao, X Lu, L Yu, X Dai, C Xiang, L Li. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering (Beijing) 2020; [Epub ahead of print] doi: 10.1016/j.eng.2020.02.006 https://doi.org/10.1016/j.eng.2020.02.006
pmid: 32292627
35
X Wu, Y Luo, J Chen, R Pan, B Xiang, X Du, L Xiang, J Shao, C Xiang. Transplantation of human menstrual blood progenitor cells improves hyperglycemia by promoting endogenous progenitor differentiation in type 1 diabetic mice. Stem Cells Dev 2014; 23(11): 1245–1257 https://doi.org/10.1089/scd.2013.0390
pmid: 24499421
36
Y Wu, X Chen, Y Zhao, Y Wang, Y Li, C Xiang. Genome-wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood-derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5-hmC in enhancer elements. Stem Cell Res Ther 2019; 10(1): 151 https://doi.org/10.1186/s13287-019-1243-8
pmid: 31151404
37
YH Li, CY Hu, NP Wu, HP Yao, LJ Li. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering (Beijing) 2019; 5(5): 940–947 https://doi.org/10.1016/j.eng.2018.11.035
pmid: 32288963
38
BJ Bosch, BE Martina, R Van Der Zee, J Lepault, BJ Haijema, C Versluis, AJ Heck, R De Groot, AD Osterhaus, PJ Rottier. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci USA 2004; 101(22): 8455–8460 https://doi.org/10.1073/pnas.0400576101
pmid: 15150417
39
G Chen, D Wu, W Guo, Y Cao, D Huang, H Wang, T Wang, X Zhang, H Chen, H Yu, X Zhang, M Zhang, S Wu, J Song, T Chen, M Han, S Li, X Luo, J Zhao, Q Ning. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130(5): 2620–2629 https://doi.org/10.1172/JCI137244
pmid: 32217835
A Lorusso, P Calistri, A Petrini, G Savini, N Decaro. Novel coronavirus (SARS-CoV-2) epidemic: a veterinary perspective. Vet Ital 2020; 56(1): 5–10
pmid: 32048818
43
N Chen, M Zhou, X Dong, J Qu, F Gong, Y Han, Y Qiu, J Wang, Y Liu, Y Wei, J Xia, T Yu, X Zhang, L Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513 https://doi.org/10.1016/S0140-6736(20)30211-7
pmid: 32007143
44
N Zhu, D Zhang, W Wang, X Li, B Yang, J Song, X Zhao, B Huang, W Shi, R Lu, P Niu, F Zhan, X Ma, D Wang, W Xu, G Wu, GF Gao, W; China Novel Coronavirus Investigating and Research Team Tan. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–733 https://doi.org/10.1056/NEJMoa2001017
pmid: 31978945
45
S Chen, G Cui, C Peng, MF Lavin, X Sun, E Zhang, Y Yang, Y Guan, Z Du, H Shao. Transplantation of adipose-derived mesenchymal stem cells attenuates pulmonary fibrosis of silicosis via anti-inflammatory and anti-apoptosis effects in rats. Stem Cell Res Ther 2018; 9(1): 110 https://doi.org/10.1186/s13287-018-0846-9
pmid: 29673394
46
D Liu, F Kong, Y Yuan, P Seth, W Xu, H Wang, F Xiao, L Wang, Q Zhang, Y Yang, H Wang. Decorin-modified umbilical cord mesenchymal stem cells (MSCs) attenuate radiation-induced lung injuries via regulating inflammation, fibrotic factors, and immune responses. Int J Radiat Oncol Biol Phys 2018; 101(4): 945–956 https://doi.org/10.1016/j.ijrobp.2018.04.007
pmid: 29976507
Z Leng, R Zhu, W Hou, Y Feng, Y Yang, Q Han, G Shan, F Meng, D Du, S Wang, J Fan, W Wang, L Deng, H Shi, H Li, Z Hu, F Zhang, J Gao, H Liu, X Li, Y Zhao, K Yin, X He, Z Gao, Y Wang, B Yang, R Jin, I Stambler, LW Lim, H Su, A Moskalev, A Cano, S Chakrabarti, KJ Min, G Ellison-Hughes, C Caruso, K Jin, RC Zhao. Transplantation of ACE2− mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11(2): 216–228 https://doi.org/10.14336/AD.2020.0228
pmid: 32257537
49
EF Cahill, H Kennelly, F Carty, BP Mahon, K English. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-induced pulmonary fibrosis. Stem Cells Transl Med 2016; 5(10): 1307–1318 https://doi.org/10.5966/sctm.2015-0337
pmid: 27388243
50
G Zheng, L Huang, H Tong, Q Shu, Y Hu, M Ge, K Deng, L Zhang, B Zou, B Cheng, J Xu. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014; 15(1): 39 https://doi.org/10.1186/1465-9921-15-39
pmid: 24708472
51
Y Zhang, ZF Ma. Impact of the COVID-19 pandemic on mental health and quality of life among local residents in Liaoning Province, China: a cross-sectional study. Int J Environ Res Public Health 2020; 17(7): E2381 https://doi.org/10.3390/ijerph17072381
pmid: 32244498
52
B Xiang, L Chen, X Wang, Y Zhao, Y Wang, C Xiang. Transplantation of menstrual blood-derived mesenchymal stem cells promotes the repair of LPS-induced acute lung injury. Int J Mol Sci 2017; 18(4): 689 https://doi.org/10.3390/ijms18040689
pmid: 28346367